Tandem Pretax Profit Margin from 2010 to 2024
TNDM Stock | USD 44.36 0.31 0.70% |
Pretax Profit Margin | First Reported 2010-12-31 | Previous Quarter (0.29) | Current Value (0.31) | Quarterly Volatility 5.28434635 |
Check Tandem Diabetes financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tandem main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.4 M, Interest Expense of 5.8 M or Selling General Administrative of 370.1 M, as well as many exotic indicators such as Price To Sales Ratio of 2.44, Dividend Yield of 0.0 or PTB Ratio of 4.71. Tandem financial statements analysis is a perfect complement when working with Tandem Diabetes Valuation or Volatility modules.
Tandem | Pretax Profit Margin |
Latest Tandem Diabetes' Pretax Profit Margin Growth Pattern
Below is the plot of the Pretax Profit Margin of Tandem Diabetes Care over the last few years. It is Tandem Diabetes' Pretax Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tandem Diabetes' overall financial position and show how it may be relating to other accounts over time.
Pretax Profit Margin | 10 Years Trend |
|
Pretax Profit Margin |
Timeline |
Tandem Pretax Profit Margin Regression Statistics
Arithmetic Mean | (3.20) | |
Geometric Mean | 0.70 | |
Coefficient Of Variation | (165.25) | |
Mean Deviation | 4.06 | |
Median | (0.68) | |
Standard Deviation | 5.28 | |
Sample Variance | 27.92 | |
Range | 13.3637 | |
R-Value | 0.76 | |
Mean Square Error | 12.74 | |
R-Squared | 0.58 | |
Significance | 0 | |
Slope | 0.90 | |
Total Sum of Squares | 390.94 |
Tandem Pretax Profit Margin History
About Tandem Diabetes Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Tandem Diabetes income statement, its balance sheet, and the statement of cash flows. Tandem Diabetes investors use historical funamental indicators, such as Tandem Diabetes's Pretax Profit Margin, to determine how well the company is positioned to perform in the future. Although Tandem Diabetes investors may use each financial statement separately, they are all related. The changes in Tandem Diabetes's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Tandem Diabetes's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Tandem Diabetes Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Tandem Diabetes. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.29) | (0.31) |
Currently Active Assets on Macroaxis
XERS | Xeris Pharmaceuticals | |
IGM | iShares Expanded Tech | |
QCOM | Qualcomm Incorporated | |
QTEC | First Trust NASDAQ 100 Technology | |
BA | The Boeing |
Check out the analysis of Tandem Diabetes Correlation against competitors. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Tandem Stock analysis
When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (2.16) | Revenue Per Share 11.817 | Quarterly Revenue Growth 0.132 | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.